The RIVAL randomized clinical trial compared robotic inguinal hernia repair with conventional laparoscopic repair. The trial was important because robotic platforms were being adopted rapidly despite limited randomized evidence showing that they improved patient outcomes. The study found no meaningful difference in short-term clinical outcomes between the two approaches. Robotic repair required greater operative time and higher procedural cost, while its potential ergonomic and technical advantages did not translate into a clear early clinical benefit in this patient population. For surgeons, RIVAL is a useful reminder that new technology should be judged against established alternatives using patient-important outcomes. Better visualization or instrument articulation may be attractive to the surgeon, but those advantages should ultimately improve pain, complications, recurrence, recovery or quality of life to justify broader adoption. The findings do not imply that robotic hernia repair has no role. Complex anatomy, recurrent disease, bilateral cases, surgeon ergonomics and institutional expertise may still influence platform selection. However, the trial supports a measured approach in routine unilateral inguinal hernia. For HCPs involved in surgical innovation, RIVAL illustrates the importance of comparative effectiveness research before widespread technology adoption.